More recently, in a pooled analysis of data from KEYNOTE-010 and KEYNOTE-042, which compared pembrolizumab to, respectively, docetaxel (second-line) and platinum-based chemotherapy (first-line) in PD-L1-positive NSCLC patients, Herbst et al. identified tissue TMB defined with a pre-specified exploratory cut-point of 175 mutations/exome and measured by WES as a potential predictor of outcomes for patients receiving single-agent pembrolizumab. Here, CD274 is linked to non-small cell lung carcinoma.